Ex-Al­ler­gan prez In­gram forges $1B deal to sell Alzheimer’s biotech to Brent Saun­ders and the new crew at Al­ler­gan

Just a year af­ter ex-Al­ler­gan pres­i­dent Doug In­gram took the helm of a low-pro­file biotech named Chase Phar­ma­ceu­ti­cals and helped steer an ex­per­i­men­tal ther­a­py for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER